The ASTEROID trial: Coronary plaque regression with high-dose statin therapy

Adnan K. Chhatriwalla; Stephen J. Nicholls; Steven E. Nissen

doi:10.2217/14796678.2.6.651

The ASTEROID trial: Coronary plaque regression with high-dose statin therapy

Adnan K. Chhatriwalla, Stephen J. Nicholls, Steven E. Nissen

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

Original language	English
Pages (from-to)	651-654
Number of pages	4
Journal	Future Cardiology
Volume	2
Issue number	6
DOIs	https://doi.org/10.2217/14796678.2.6.651
Publication status	Published or Issued - Nov 2006
Externally published	Yes

Keywords

Atherosclerosis
Cholesterol
Coronary artery disease
HMG Co-A reductase inhibitors
Intravascular ultrasound
Low-density lipoprotein cholesterol
Statins

ASJC Scopus subject areas

Molecular Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.2217/14796678.2.6.651

Cite this

@article{ed8c54cafd6e4d8091e8f018125398cc,

title = "The ASTEROID trial: Coronary plaque regression with high-dose statin therapy",

abstract = "A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.",

keywords = "Atherosclerosis, Cholesterol, Coronary artery disease, HMG Co-A reductase inhibitors, Intravascular ultrasound, Low-density lipoprotein cholesterol, Statins",

author = "Chhatriwalla, {Adnan K.} and Nicholls, {Stephen J.} and Nissen, {Steven E.}",

year = "2006",

month = nov,

doi = "10.2217/14796678.2.6.651",

language = "English",

volume = "2",

pages = "651--654",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - The ASTEROID trial

T2 - Coronary plaque regression with high-dose statin therapy

AU - Chhatriwalla, Adnan K.

AU - Nicholls, Stephen J.

AU - Nissen, Steven E.

PY - 2006/11

Y1 - 2006/11

N2 - A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

AB - A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) investigated the impact of high-dose rosuvastatin therapy on the rate of atheroma progression in patients with coronary artery disease. Serial intravascular ultrasound (IVUS) was performed in 349 patients at baseline and following 24 months of therapy with rosuvastatin 40 mg/day. Rosuvastatin therapy lowered low-density lipoprotein cholesterol to 60.8 mg/dl and raised high-density lipoprotein cholesterol by 14.7%. This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events.

KW - Atherosclerosis

KW - Cholesterol

KW - Coronary artery disease

KW - HMG Co-A reductase inhibitors

KW - Intravascular ultrasound

KW - Low-density lipoprotein cholesterol

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=33750975918&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.6.651

DO - 10.2217/14796678.2.6.651

M3 - Article

C2 - 19804256

AN - SCOPUS:33750975918

SN - 1479-6678

VL - 2

SP - 651

EP - 654

JO - Future Cardiology

JF - Future Cardiology

IS - 6

ER -

The ASTEROID trial: Coronary plaque regression with high-dose statin therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this